NEOVACS 
By Paris, December 9, 2013 - NEOVACS (Alternext Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today that it has successfully enrolled the first patients in the Phase IIb study of TNF-Kinoid for the treatment of rheumatoid arthritis (RA). These patients have received a first injection of the Kinoid.
The TNF-Kinoid's development plan is in line with the schedule announced by the Company at the time of its capital increase in March 2013. Proceeds from the capital increase are financing the study.
Neovacs has received consents from the regulatory authorities and ethics committees in Belgium, Moldova, Georgia, Hungary, Czech Republic, Poland and Lebanon. Further approvals will be obtained soon in the other countries of the study.
« These first inclusions within scheduled timelines are a major milestone in Neovacs' development. The study has been rapidly and unevently approved in many sites across numerous countries, outlining the need for novel therapeutic strategies and the interest raised by Neovacs kinoid. Over 15 study centers are now operational, and dozens of patients have been screened [1] for enrollement. The majority of the remaining centers should open before the end of the year, allowing us to rapidly enroll more patients and finalize the recruitment on schedule » commentsPierre Vandepapelière, Chief Medical Officer of Neovacs.
"There remains a need for new therapies for chronic inflammatory diseases. Targeting TNF
